Briefing
Abstract RF3-05: Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial
ctDNA was detected by Reveal in 54/159 (34.0%) patients at least once and was associated with relapse (HR 20.62, P<0.0001). Of patients who relapsed by 24 months, 34/38 (89.5%) had prior ctDNA detection. Agreement with ddPCR was 94.5% (950/1005 timepoints). Among detections, 44.8% were first found by the tissue-free assay and 6.9% by ddPCR. Median time from first detection to relapse was 7.9 months with Reveal vs 5.7 months with ddPCR (HR 0.6, P=0.0574).
- n: 1,062 timepoints from 159 patients; 1,012 (95.3%) successfully analyzed with the tissue-free assay; 1,005 timepoints compared with ddPCR
- Assay: Guardant Reveal (tissue-free methylation) compared with digital droplet PCR (1-2 patient-specific variants)